Chengdu Nuohe Shengtai Biotechnology

Chengdu Nuohe Shengtai Biotechnology is a biopharmaceutical company specializing in the research and development of peptide drugs and complex formulations. As a core subsidiary of Beijing Nuohe Shengtai Pharmaceutical Technology, the company focuses on high-barrier therapeutic areas including metabolic diseases, cardiovascular conditions, and central nervous system disorders. The firm utilizes proprietary platforms for peptide synthesis and long-acting drug delivery to develop both innovative new chemical entities and high-end biosimilars. Their pipeline is notably strong in the incretin space, featuring several GLP-1 receptor agonists in various stages of clinical and preclinical development. Based in the Tianfu International Bio-Town, the company plays a significant role in the regional biotechnology ecosystem in Western China.